Replimune stock.

Also, insider Konstantinos Xynos sold 7,313 shares of Replimune Group stock in a transaction that occurred on Thursday, November 16th. The stock was sold at …REPL Stock 12 Months Forecast. $57.33. (396.79% Upside) Based on 4 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $57.33 with a high forecast of $70.00 and a low forecast of $42.00. The average price target represents a 396.79% change from the last price of $11.54.Replimune | Stock Quote & Chart Investors & Media Overview Events and Presentations Press Releases Corporate Governance Financials & Filings Stock Information Publications Email Alerts Investor Contact Select Page Stock Quote & Chart Stock Quote & Chart Historical Price Analyst Coverage Change Volume Today's Open Previous Close Today's HighOct 15, 2020 · Shares of Replimune Group ( REPL -2.97%) were soaring 13.3% higher as of 11:01 a.m. EDT on Thursday after rising as much as 22.4% earlier in the day. The big jump resulted from the company's ...

About Replimune Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of …Real time Replimune Group (REPL) stock price quote, stock graph, news & analysis.

From the period between 2010 and 2023, Replimune, Working Capital regression line of its data series had standard deviation of 201,967,139 and standard deviation of 201,967,139. Replimune Operating Expenses is quite stable at the moment as compared to the past year. The company's current value of Operating Expenses is estimated at 191.06 Million.PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …

According to the issued ratings of 6 analysts in the last year, the consensus rating for Replimune Group stock is Buy based on the current 6 buy ratings for REPL. The average twelve-month price prediction for Replimune Group is $51.33 with a high price target of $70.00 and a low price target of $34.00. Learn more on REPL's analyst rating …Replimune Group Stock Forecast · Over the next 52 weeks, Replimune Group has on average historically risen by 19.6% based on the past 5 years of stock ...Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies.WOBURN, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application for its lead …In other Replimune Group news, insider Pamela Esposito sold 5,358 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $20.01 ...

Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.

PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …

Replimune's shares could be a promising option for shorting if the upcoming trial results are negative, as I believe is very likely. In this scenario, Replimune's stock could potentially fall by ...Find the latest Scholar Rock Holding Corporation (SRRK) stock quote, history, news and other vital information to help you with your stock trading and investing.WOBURN, Mass.Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic ...Nov 24, 2023 · According to the issued ratings of 6 analysts in the last year, the consensus rating for Replimune Group stock is Buy based on the current 6 buy ratings for REPL. The average twelve-month price prediction for Replimune Group is $51.33 with a high price target of $70.00 and a low price target of $34.00. Learn more on REPL's analyst rating history. PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 11.71 +0.53 (+4.74%) At close: 04:00PM EST. 11.71 0.00 (0.00%) After hours: 04:20PM EST.

Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued.Earnings for Replimune Group are expected to decrease in the coming year, from ($3.53) to ($3.93) per share. Replimune Group has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 8th, 2024 based off prior year's report dates.Replimune | Stock Quote & Chart Investors & Media Overview Events and Presentations Press Releases Corporate Governance Financials & Filings Stock Information Publications Email Alerts Investor Contact Select Page Stock Quote & Chart Stock Quote & Chart Historical Price Analyst Coverage Change Volume Today's Open Previous Close Today's High Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory …Altria stock (NYSE:MO) boasts a hefty 9.6% dividend yield, making its investment appeal stronger than ever. Despite ever-persistent concerns surrounding the tobacco industry and rising interest ...About Replimune Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of …19 Sep 2023 ... The inducement awards consist of a non-qualified stock option to purchase 125,000 shares of the Company's common stock and restricted stock ...

WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicenter, Phase 1 study of RP2 as a single agent and in combination with nivolumab.Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued.

Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.11.32. -0.21. -1.82%. WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio ...See Replimune Group, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. ... Based on 10 analysts giving stock ratings to REPL in the past 3 months. EPS. …Replimune's shares could be a promising option for shorting if the upcoming trial results are negative, as I believe is very likely. In this scenario, Replimune's stock could potentially fall by ...Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous squamous cell carcinoma, are expected Q4 of ...Replimune Group Stock Performance Shares of NASDAQ REPL opened at $11.71 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of …Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ...Earnings announcements can affect a stock's price. This table shows the stock's price the day before and the day after recent earnings reports, including the ...

About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize …

Jan 4, 2023 · The inducement awards consist of a non-qualified stock option to purchase 82,500 shares of the Company’s common stock and restricted stock units representing 55,000 shares of the Company’s common stock. The option has an exercise of $27.20 per share, which is equal to the closing price of the Company’s common stock on the date of grant ...

Dec 3, 2023 · Replimune Group, Inc. ( NASDAQ:REPL – Get Free Report) shares were down 3.4% during trading on Friday . The company traded as low as $10.80 and last traded at $10.80. Approximately 15,578 shares traded hands during trading, a decline of 97% from the average daily volume of 618,826 shares. The stock had previously closed at $11.18. Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 11.71 +0.53 (+4.74%) At close: 04:00PM EST. 11.71 0.00 (0.00%) After hours: 04:20PM EST.Novartis AG. -0.52%. CHF176.38B. REPL | Complete Replimune Group Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Replimune ends selloff after FDA response to mid-stage cancer trial. Following four straight sessions of losses, oncology-focused biotech Replimune Group ( NASDAQ: REPL) added ~7% on Monday after ...29 Jun 2020 ... The offering consisted of shares of Replimune's common stock and pre‑funded warrants to acquire shares of its common stock. The shares were ...Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added ... If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Replimune Group, Inc. ( NASDAQ:REPL – Get Free Report) shares were down 3.4% during trading on Friday . The company traded as low as $10.80 and last …At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies.­ Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all ...

Nov 3, 2022 · About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death ... All securities in the offering are being offered by Replimune. In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of its common stock from Replimune at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on October …Nov 24, 2023 · According to the issued ratings of 6 analysts in the last year, the consensus rating for Replimune Group stock is Buy based on the current 6 buy ratings for REPL. The average twelve-month price prediction for Replimune Group is $51.33 with a high price target of $70.00 and a low price target of $34.00. Learn more on REPL's analyst rating history. Instagram:https://instagram. rei energybmw 740is a 1979 silver dollar worth anythinganheuser busch. Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immuno-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune … how much is a kennedy 50 cent piece worthbicentennial coins worth About Replimune Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of …Get the latest Replimune Group Inc. (REPL) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. whats the best online banking app A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Historical daily share price chart and data for Replimune since 2018 adjusted for splits and dividends. The latest closing stock price for Replimune as of November 24, 2023 is 10.39.. The all-time high Replimune stock closing price was 52.65 on December 01, 2020.; The Replimune 52-week high stock price is 29.52, which is 184.1% above the current share …